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Background: The origins of the inhibition of DNAJB6 against amyloid formation are unknown.
Results: DNAJB6 inhibits fibril formation of the A42 peptide from Alzheimer disease at low sub-stoichiometric molar ratios
through strong binding to aggregated species.
Conclusion: Such sequestration prevents the growth and the proliferation of the aggregates.
Significance: The efficacious action of the chaperone against amyloid formation involves interactions with multiple growing
aggregates.
The human molecular chaperone protein DNAJB6 was
recently found to inhibit the formation of amyloid fibrils from
polyglutamine peptides associated with neurodegenerative dis-
orders such as Huntington disease. We show in the present
study that DNAJB6 also inhibits amyloid formation by an even
more aggregation-prone peptide (the amyloid-beta peptide,
A42, implicated in Alzheimer disease) in a highly efficient
manner. By monitoring fibril formation using Thioflavin T
fluorescence and far-UV CD spectroscopy, we have found that
the aggregation of A42 is retarded by DNAJB6 in a concentra-
tion-dependent manner, extending to very low sub-stoichio-
metric molar ratios of chaperone to peptide. Quantitative
kinetic analysis and immunochemistry studies suggest that the
high inhibitory efficiency is due to the interactions of the chap-
erone with aggregated forms of A42 rather than the mono-
meric form of the peptide. This interaction prevents the growth
of such species to longer fibrils and inhibits the formationof new
amyloid fibrils through both primary and secondary nucleation.
A low dissociation rate of DNAJB6 from A42 aggregates leads
to its incorporation into growing fibrils and hence to its gradual
depletion from solution with time.When DNAJB6 is eventually
depleted, fibril proliferation takes place, but the inhibitory
activity can be prolonged by introducing DNAJB6 at regular
intervals during the aggregation reaction. These results reveal
the highly efficacious mode of action of this molecular chaper-
one against protein aggregation, and demonstrate that the role
of molecular chaperones can involve interactions with multiple
aggregated species leading to the inhibition of both principal
nucleation pathways throughwhich aggregates are able to form.
Amyloid fibrils are highly ordered protein aggregates char-
acterized by a repeating substructure of-strands oriented per-
pendicularly to the fiber axis, an arrangement which gives rise
to a characteristic cross- diffraction pattern (1, 2). Since the
amyloid state is characterized by a dense network of hydrogen
bonding connecting groups within the polypeptide backbone
common to all peptides and proteins, the ability to form amy-
loid fibrils is a generic property of polypeptides (3), although the
propensity to form fibrils under specific conditions is modu-
lated by the amino acid sequence (4, 5).
Over 40 human proteins are found in amyloid deposits
associated with human diseases, including Huntington and
Alzheimer disease (1, 6). Alzheimer disease (AD)2 is one of the
most common forms of dementia affecting over 40million peo-
ple worldwide. Hallmarks of this disease include extracellular
amyloid deposits containing the amyloid  peptide (A) and
intracellular neurofibrillar tangles of the hyper-phosphorylated
protein tau (7). Endogenously formed A peptides are largely
composed of 39–43 residues, with the most common species
containing either 40 (A40) or 42 (A42) residues. The two
additional residues at the C terminus of A42 compared with
A40 has emerged as a factormodulating the propensity of this
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peptide to aggregate and its associated toxicity, with A42
being more aggregation prone than A40. Furthermore, the
ratio of A42 to A40 has been found to be higher in AD
patients than in healthy controls (8, 9).
It is increasingly evident that AD is associated with neuronal
damage resulting from the aggregation of the A peptide,
chiefly A42, and also of tau, which is likely to occur as a down-
stream process. We use the term aggregate to refer to any spe-
cies containing two or more A42 peptides and oligomer to
refer specifically to low relative molecular weight aggregate
species containing typically 2–15 molecules (10). Recent evi-
dence suggests that this toxicity is largely associated with low
molecular weight oligomers rather than with monomeric spe-
cies or with the mature amyloid fibrils (10–13). This observa-
tion indicates that a fruitful therapeutic strategy to reduce the
toxicity associated with the aggregation process would be to
target specifically the pathways that lead to the formation of
such oligomeric toxic species rather than aim to arrest the
fibril formation itself. A fundamental prerequisite to achieve
such selective targeting is a detailed understanding of the
molecular mechanism underlying fibril formation in the
presence and absence of molecular species able to perturb
the aggregation process. In this context, kinetic analysis in
combination with experimental measurements is emerging
as a powerful tool to provide a mechanistic description of the
aggregation process and its inhibition (10, 14–19). Kinetic
studies have shown in vitro that A42 aggregation occurs by
a double nucleation mechanism (10, 20), with the primary
nucleation of monomers in solution being significantly
slower than the secondary nucleation catalyzed by the sur-
faces of amyloid fibrils (10).
A wide range of molecules have been reported to influence
the aggregation process of A peptides, including small mole-
cules, designed peptides, antibodies and other proteins (15, 19,
21–23).3 A crucial class of inhibitors in living systems is that of
molecular chaperones, which in addition to their role in assis-
ting protein folding and assembly (24, 25), are known to sup-
press aggregation induced by heat shock or other proteotoxic
stresses (26–28), and play a key role in suppressing amyloid
formation and promoting clearance of misfolded species (29,
30). Moreover, the chaperone B-crystallin (HSPB5) is overex-
pressed in post mortem brains of AD patients and is co-local-
ized with A aggregates in eye lenses from such patients (31,
32), and in addition retards A fibril formation in vitro (21, 22).
Recent kinetic studies reveal that the capability of natural
molecular chaperones to inhibit aggregation may involve the
suppression of single specific steps in the aggregation process.
For instance, a chaperone belonging to the Brichos family (19)
has been found to suppress specifically the secondary nucle-
ation step of A42 aggregation.3 Despite the fact that such inhi-
bition does not affect the total amount of mature fibrils that are
eventually formed, the suppression of this specific step is highly
efficient in decreasing the numbers of oligomers generated dur-
ing the reaction and hence the toxicity associated with the
aggregation process (33).3
DNAJB6 is a human molecular chaperone belonging to the
Hsp40 heat shock protein family. This chaperone has been
recently found to perturb the formation of fibrils by polyglu-
tamine peptides (34), which are involved in neurodegenerative
disorders such as Huntington disease (35, 36). In the present
work, we show that DNAJB6 is a potent inhibitor of the aggre-
gation of A42, acting in a concentration-dependentmanner at
remarkably low stoichiometric ratios. We demonstrate by
means of kinetic analysis and immunochemistry experiments
that such high efficiency originates from the capability of
DNAJB6 to sequester effectively the A42 aggregates, which
propagate the amyloid conversion reaction, thereby preventing
their growth and limiting their ability to proliferate through
secondary nucleation.
EXPERIMENTAL PROCEDURES
Peptides and Proteins—A42. Human A peptide, A(1–
42), UniProtKB IDP05067, residues 672–713, with anN-termi-
nal methionine residue, also corresponding to residue 671 of
APP, (MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGL-
MVGGVVIA) was expressed recombinantly in Escherichia
coli BL21 DE3 star PLysS and purified essentially as described
previously (10, 18, 37) to obtain a pure monomers from which to
initiate the aggregation reaction and achieve high reproducibility.
DNAJB6—HumanDNAJB6b (isoform b, UniProt IDO75190–2)
with a hexa-His tag was expressed recombinantly in E. coli
ER2566 and purified as described previously (34) but with an
additional washing step using 8 M urea during the affinity chro-
matography in order to remove bound bacterial proteins (38).
Just prior to its use, DNAJB6 was dialyzed into the assay buffer
(20 mM sodium phosphate buffer pH 8, 0.2 mM EDTA, 0.02%
sodium azide) using Slide-A-Lyser MINI (Thermo Scientific,
Rockford, IL).
B-Crystallin—Human B-crystallin (UniProtKB ID P02511)
was recombinantly expressed and purified as previously
described (39). The protein was desalted using PD10 desalting
column, (GE Healthcare, Little Chalfont, UK) eluted in assay
buffer, and concentrated, when necessary, by Nanosep 3 K
Omega (Pall Life Sciences, PortWashington, NY), and stored at
20 °C until use.
Human Serum Albumin (HSA)—HSA (fatty acid free, 99%
pure) was obtained from Sigma (Stockholm, Sweden) and puri-
fied as described previously (40).
Determination of ProteinConcentration—Protein concentra-
tions are reported as monomer equivalents for DNAJB6 and
B-crystallin, determined as the mean values between the val-
ues obtained from the Bradford assay (41, 42), using BSA as a
reference, and the absorbance at 280 nm taken from their
respective theoretical extinction coefficients. The concentra-
tion of A42was determined using absorbance at 280 nmof the
collected monomer fraction, using   1400 mol1cm1 as
verified using amino acid analysis after acid hydrolysis.
Denaturing Electrophoresis—Denaturing gel electrophoresis
was performed using precast 4–12% NuPAGE SDS-PAGE
Bis-Tris gels (Invitrogen, Stockholm, Sweden) according to the
manufacturer’s instructions. Samples were dilutedwith lithium
dodecyl sulfate sample buffer (4) (Invitrogen, Stockholm,
Sweden) and electrophoresis was run in 50 mM MES buffer pH
3 Cohen, S. I. A., Arosio, P., Presto, J., Kurudenkandy, F. R., Biverstal, H. et al
2014, submitted publication.
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7.3. Gels were silver-stained according to established protocols
(43) for maximized sensitivity, and scanned on an Image Scan-
ner III with the Labscan software (GE Healthcare LifeSciences,
Uppsala, Sweden).
CD Spectroscopy—Ellipticity was recorded between 250 and
185 nm in a quartz (QS) cuvette with 10 mm path length at
37 °C using a Jasco J-815 CD spectrometer. The samples were
stirred between measurements but not during measurement.
The scanning rate was 50 nm/min, the digital integration time
per data point (D.I.T.) was 8 s, the sensitivity was set to the
standard value, and the reported data were averaged over
three accumulations. The data were cropped at the wavelength
where the voltage exceeded 800 V, and the background signal
from the buffer (5mM sodium phosphate buffer, pH 8.0 with 40
mM NaF) or the buffer including 0.05 M DNAJB6 was sub-
tracted. The A42 concentration was 5 M, and the DNAJB6
concentration 0.05 M.
Aggregation Kinetics—Aggregation kinetics were monitored
as described previously (18) using a Thioflavin T (ThT) fluores-
cence assay based on the enhanced quantum yield of ThT
fluorescence as the dye binds to amyloid fibrils. All experiments
were performed in the assay buffer (20 mM sodium phosphate
buffer pH 8, 0.2 mM EDTA, 0.02% sodium azide) with 10 M
ThT in microplate wells (Mikroplate Corning 3881, 96-well,
low-binding, half-area, Corning Incorporated Life Sciences,
Acton, MA) with 70 l solution per well
Samples were prepared on ice in low binding tubes using
freshly prepared monomeric A42 at the final concentrations
stated in the text and at least three measurements per sample
were recorded. ThT fluorescence was recorded at 2-min inter-
vals under quiescent conditions without agitation at 37 °C,
using a Fluostar Omega or Optima plate reader (BMGLabtech,
Offenburg, Germany) with a 440 nm excitation filter and a 480
nm emission filter. In Fig. 1, the total fluorescence intensity is
shown, in the other figures the relative intensities normalized to
1 are presented.
Production of A42 Seed Fibrils—To produce A42 seed
fibrils, 7 M A42 monomer with 10 M ThT was incubated
and fibril formationwasmonitored byThT fluorescence for 2 h,
at which point equilibrium was reached, and a suspension of 7
M seed fibrils was obtained. The seed fibrils were sonicated for
2 min.
Kinetic Analysis of Unseeded Reactions—The time evolution
of the total fibril massM(t) in the presence of both primary and
secondary nucleation events is described by the integrated rate
law in Equation 1 (10, 44, 45):
Mt
M
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
	
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

e	t
where the kinetic parameters B	, C	, 	, 	∞, and
	∞ are func-
tions of combinations of themicroscopic rate constants kk2
and knk2, where kn, k, and k2 are the primary nucleation,
fibril elongation, and secondary nucleation rate constants,
respectively.
As DNAJB6 could alter the global aggregation profile by
inhibiting one ormore of the individual microscopic events, we
have carefully identified the microscopic steps that are inhib-
ited by the molecular chaperone. This objective was achieved
by applying Eq. 1 to describe the global profiles of the unseeded
reactions shown in Fig. 3, A and B, and comparing the set of
microscopic rate constants kk2 and knk2 required to describe
the time evolution of the fibril formation in the absence and
presence of DNAJB6.
Filter Trap Assay—3MA42 solutions were prepared as for
the kinetic aggregation studies, in the absence and presence of
DNAJB6 at the final concentrations as stated, and the time evo-
lution of the ThT fluorescence was recorded. At selected time
positions, as indicated by the asterisks, and at the end of the
experiment, aliquots of sample were extracted, mixed with PBS
containing 1% SDS, and added to a cellulose acetate membrane
with 0.2 m pores (GE Healthcare, Uppsala, Sweden) with a
vacuum device. The membranes were washed twice with PBS
containing 1% SDS, and thenwith PBSwithout SDS. Themem-
brane was blocked with nonfat dry milk in PBS with 0.1%
FIGURE 1. A42 aggregation in the absence and presence of the human molecular chaperone DNAJB6. A, fibril formation by 3 M A42 solutions was
monitoredby following the increase in ThT fluorescence (black); the inhibitory effect ofDNAJB6 (red) was comparedwith that of humanB-crystallin (blue) and
HAS (green). Molar ratios between A42 and the proteins were 1:0.1. B, aggregation reaction profiles of ThT fluorescence of A42 in the absence (black) and in
the presence of DNAJB6 at molar ratios of peptide to chaperone from 1:0.01 to 1:0.13, color coded as indicated to the right. 4 independent incubations per
sample were performed. C, silver-stained SDS-PAGE shows the purity of the chaperone with and without the washing step with 8 M urea to remove proteins
stronglybound toDNAJB6: lane 1,molecularweightmarker (kDa); lane 2, urea-washedDNAJB6; lane 3, not urea-washedDNAJB6; lanes 4 and 5: first and second
wash fraction (with andwithout urea, respectively) resulting in DNAJB6 in lane 2; lane 6, wash fractionwithout urea resulting in DNAJB6 in lane 3. The asterisks
are positioned above bands indicating minor amounts of DNAJB6 degradation product (***), DNAJB6 monomers with His-tag (**), and DNAJB6 dimers (*).
DNAJB6 Suppresses A42 Fibril Formation
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Tween-20 for 1 h, and thereafter primary polyclonal rabbit anti-
bodies for DNAJB6 (Innovagen, Lund, Sweden) diluted 1:1000
and A, 6E10 monoclonal mouse (Covance, Princeton, NJ)
diluted 1:1000, were added to the membrane followed by an
incubation for 1 h. After washing in PBS with and without
Tween-20, themembranes were incubated for 1 h with second-
ary antibodies from LiCORE: IRDye 800CW goat anti-rabbit
and IRDye 680RD goat anti-mouse in nonfat dry milk in PBS
with Tween-20. The membranes were washed, dried, and
stored in the dark until analyzed. The fluorescence emission of
the membranes was imaged at two wavelengths using an Odys-
sey CLX IR imaging system (LICOR, Cambridge, UK).
RESULTS
DNAJB6 Inhibits Fibril Formation by the A42 Peptide—We
investigated the effect of DNAJB6 on fibril formation by highly
purified recombinant human A42 peptide under quiescent
conditions by monitoring the intensity of ThT fluorescence
reporting on the formation of amyloid fibrils. At the concentra-
tion of A42 used as a reference point in this work (3 M), we
observed a reaction half time, defined as the time for half of the
initial monomeric pool to form ThT-sensitive aggregates, t1⁄2
1.5 h (Figs. 1, A and B and 3), in close agreement with an
earlier report (10). However, in the presence of even a sub-
stoichiometric concentration of the molecular chaperone
DNAJB6 at a molar ratio of 1:0.1 A42 to DNAJB6, the aggre-
gation process was fully suppressed for 30 h (Fig. 1A) with no
observable ThT signal being detected over this length of time.
The concentrations and molar ratios are given throughout this
work as monomer equivalents, since DNAJB6 is an oligomeric
protein with varying numbers of monomers per oligomer; a
representative SDS-PAGE gel of the highly purified protein is
shown in lane 2 in Fig. 1C. Addition of a non-chaperone pro-
tein, human serum albumin (HSA), at a molar ratio of 1:0.1 did
not affect the rate of fibril formation by A42. Moreover, addi-
tion at the same molar ratio (1:0.1) of B-crystallin, a member
of the family of small heat shock proteins previously shown to
inhibit A42 peptide aggregation (21) at higher concentrations,
did not affect the fibril formation process when used under
conditions where the A42 was in significant excess. Hence,
DNAJB6 exhibits a particularly potent inhibitory effect with
respect to other proteins.
To analyze the effect of DNAJB6 on A42 fibril formation in
more detail and determine its mechanism of action, we per-
formed a series of kinetic experiments by varying systematically
the DNAJB6 concentration while maintaining the concentra-
tion of A42 fixed (Fig. 1B). These results show that DNAJB6
causes a concentration-dependent retardation of A42 aggre-
gation, and is effective already at highly sub-stoichiometric
concentrations (1:0.03 molar ratio). The t1/2 increases progres-
sively fromca. 1.7 h in the absence of chaperone to 36 h at 1:0.08
A42 to DNAJB6 molar ratio. At DNAJB6 concentrations
above 0.3 M, corresponding to a molar ratio of A42 to
DNAJB6 of 1:0.1, fibril formation was not observed during the
time-frame of the experiment (45 h).
The analysis of the rates of fibril formation using ThT fluo-
rescence is supported bymeasurements using far-UVCD spec-
troscopy, which can detect the characteristic -sheet structure
of amyloid fibrils generated by the self-assembly of the peptide
even in the absence of ThT reactive species. The spectra of
A42 change from those characteristic of the disordered struc-
ture of the monomer to the -sheet structure of the fibrils,
which exhibit a characteristicminimum at around 218 nm. At a
1:0.01 A42:DNAJB6 molar ratio, DNAJB6 delays the -sheet
structure formation of a 5MA42 solution such that the time
required to reach the end point of the aggregation reaction
increases from 3 h (Fig. 2A) to 17 h (Fig. 2B), in excellent agree-
ment with the ThT data shown in Fig. 1A, thereby confirming
that the formation of fibrils is delayed in the presence of
DNAJB6.
Kinetic Analysis of Unseeded and Seeded Reactions Reveals
that DNAJB6 Suppresses Both Primary and Secondary Nucle-
ation Events—To gain insight into the microscopic inhibition
mechanism of the chaperone, we performed kinetic studies of
A42 aggregation reactions at different DNAJB6 and A42
concentrations (15) (Fig. 3, A and B). Analysis of such kinetic
data has shown that the scaling of the half-times of the aggre-
gation reaction profiles as a function of the total protein con-
centration follows a power law whose exponent contains
important information about the microscopic events underly-
ing themacroscopic aggregation behavior (16, 44, 45). From the
measured half-times of the A42 aggregation data obtained for
different peptide concentrations, we obtain a scaling exponent
of 1.33 in the absence of DNAJB6 (Fig. 3C), consistent with
our previous findings (10). This exponent originates from the
situation (10) where secondary nucleation events dominate the
generation of new fibrils, although primary nucleation events
are still present and reduce the exponent from the limiting
value of3/2, which corresponds to pure secondary nucleation
events (10, 16, 44, 45). In the presence of DNAJB6 (Fig. 3A), the
lag times increase and the scaling exponent decreases to1.45
(Fig. 3C), an observation that suggests that, under these condi-
tions, the action of the molecular chaperone originates mainly
through its inhibitory effect on primary nucleation reactions,
thereby increasing the relative importance of secondary nucle-
ation events.
This conclusion is confirmed by the detailed analysis of the
effects of DNAJB6 on the microscopic events involved in
the aggregation of the A42 peptide. To this effect, to obtain
FIGURE 2. DNAJB6 delays the conversion of A42 from unstructured
monomers to-sheet structures. Far-UVCD spectra of 5MA42 solutions
showing the appearance of the characteristic -sheet structure signal with a
minimum intensity at c.a. 218 nm at different time points at 37 °C in A the
absence and B, the presence of 0.05 M DNAJB6. In A the signal from the
buffer has been subtracted, in B the signal from the buffer including 0.05 M
DNAJB6 has been subtracted.
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the rate constants describing themicroscopic events of primary
and secondary nucleation and fibril elongation, we performed
global fits to the integrated rate laws for filamentous growth
(10, 20). In this approach, a set of kinetic profiles recorded at
different initial concentrations of soluble peptide are fitted to a
single rate law with a single set of rate constants, thereby plac-
ing strong constraints on the fitting parameters. We then com-
pared the microscopic rate constants required to describe the
time evolution of fibril formation in the presence of DNAJB6
with the set of rate constants estimated previously in the
absence of the chaperone (10). This analysis shows that the
molecular chaperone inhibits both primary and secondary
nucleation events (Fig. 3,D and E), but that the inhibitory effect
on primary nucleation events is significantly greater. Indeed,
the combination of kinetic constants describing the primary
pathway (17, 44, 46), knk decreases by a remarkable 10 orders
ofmagnitude (Fig. 3D), while the corresponding set of rate con-
stants governing the secondary pathway, k2k, decreases only
by 2 orders ofmagnitude (Fig. 3E) as themolecular chaperone is
introduced into the reaction mixture. This result is therefore
fully consistent with the change of the scaling exponent toward
the theoretical value corresponding to the presence of second-
ary nucleation events only (Fig. 3C).
Consideration of the stoichiometry of the system suggests
that we can exclude the possibility that the inhibitory effect
discussed above is due simply to binding between DNAJB6 and
monomericA42. Indeed, even if several A42 peptides (Mw
4.5 kDa) could bind to each DNAJB6monomer (Mw 27 kDa)
at a 1:0.01 molar ratio, this effect would reduce the free A42
monomer concentration only by a few percent, which would
have only aminor impact on the observed aggregation rate.We
can conclude, therefore, that DNAJB6 affects primary nucle-
ation processes by interacting with the aggregated species that
result from the nucleation process, hence suppressing their
growth into longer fibrils that are required for the effective
catalysis of the aggregation reaction by secondary processes
(10).
To investigate further the inhibition of the elongation and
secondary processes by DNAJB6, we performed seeded aggre-
gation experiments. Under such conditions, where the reaction
is initiated by adding a well-defined concentration of pre-
formed seed fibrils to solutions of the monomeric peptide, the
overall kinetics can become largely independent of the nucle-
ation processes since the presence of pre-formed fibrils circum-
vents the nucleation barrier (47). As such, seeded experiments
can be a powerful tool to probe the changes in a specific micro-
scopic process in the aggregation pathway, the elongation step.
The results, shown in Fig. 3F, indicate that DNAJB6 is also
effective in inhibiting fibril formation in a concentration-de-
pendentmannerwhen the process is initiated by the addition of
1%w/wof pre-formed fibrils to the reactionmixture.Moreover,
the presence of themolecular chaperone restores the lag-phase
which is very short in the absence of DNAJB6. This observation
indicates that DNAJB6 interacts not only with aggregates
formed as a result of primary nucleation but alsowith the struc-
tures originating from secondary nucleation, whose formation
FIGURE 3.Kinetics of A42 aggregation in thepresenceofDNAJB6. Reaction profiles for ThT fluorescence for unseeded aggregation of (A) 3MA42 solutions
in theabsenceofDNAJB6 (red) andwithDNAJB6present at amolar ratioofpeptide to chaperoneof 1:0.001 (green), 1:0.005 (maroon) and1:0.01 (purple), and (B) A42
solutions in theconcentration range2.2–8.0M in thepresenceof0.225MDNAJB6.The lines inAandB represent the integrated rate lawforA42aggregation fitted
totheexperimentaldata.C,half-timesasafunctionof the initialA42concentration inthepresenceandabsenceofDNAJB6.Notethechangeofexponent from1.33
to 1.45 induced by the presence of DNAJB6, showing the capability of the chaperone to suppress primary nucleation events. D and E, set of microscopic rate
constants corresponding to thekinetic analysis shown inAandBnormalized to thevalues in theabsenceof chaperoneasa functionofDNAJB6:A42molar ratios. For
unseeded reactions the inhibition of primary nucleation events (knk/knk* (D)) is significantly largerwith respect to secondary nucleation events (k2k/k2k* (E)). F,
reactionprofiles of 3MA42 solutionswith 1%seeds in the absenceofDNAJB6 (red) andwith 1:0.01 (blue), 1:0.02 (green), and1:0.05 (orange)monomer equivalents
of DNAJB6 showing the capability of the chaperone to suppress secondary nucleation events.
DNAJB6 Suppresses A42 Fibril Formation
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is catalyzed by the surface of seed fibrils, and prevents the elon-
gation and the autocatalyticmultiplication of aggregatedA42.
Furthermore, it is also likely that DNAJB6 interacts with the
added seeds themselves since their elongation is suppressed.
Taken together, the data indicate that DNAJB6 reduces the rate
of fibril formation by inhibiting all the main classes of events in
the reaction process, primary and secondary nucleation and
elongation; moreover, the kinetic analysis shows that specific
interactions with species formed after primary and secondary
nucleation are the major origin of the very large magnitude of
this inhibition effect (Fig. 4).
We note that the molecular chaperone delays but does not
suppress completely the fibril formation process. In particular,
under seeding conditions, the reaction profiles exhibit signifi-
cantly different lag-phases in the presence and absence of
DNAJB6 but very similar growth phases (Fig. 3F). This obser-
vation suggests that during the initial phases of aggregation, the
molecular chaperone interacts with all aggregated species, but
that after a given incubation time, which is proportional to the
initial chaperone concentration (Fig. 3F), the inhibitory effect
disappears. This observation indicates that at this incubation
time the chaperone is no longer effective, suggesting the possi-
bility that it could be depleted from the solution, while A42 is
still present as free monomers able to participate in the aggre-
gation reaction.
DNAJB6 Sequesters Growing A42 Species and Is Incorpo-
rated into the Fibrils—To test whether or not aggregating A42
is able to deplete DNAJB6 from the solution over time, we per-
formed immunoblot analysis of samples taken at different time
points during the A42 aggregation reactions performed in the
absence (Fig. 5A) and presence of DNAJB6 at different concen-
trations (Fig. 5, B–D). The resulting fibrils, which are SDS-in-
soluble, were trapped using a cellulose acetate membrane and
the composition of the trappedmaterial was probed using anti-
bodies against A42 and DNAJB6. Remarkably, under condi-
tions where the A42 fibrils were formed in the presence of
DNAJB6, the chaperone was also detected at the filtration
membrane, indicating that it is strongly associated with the
SDS-insoluble fibrils. We then evaluated the capability of
DNAJB6 to block on-going aggregation reactions by adding ali-
quots of the chaperone at different time points during the incu-
bation (Fig. 6A). Inhibition of the aggregation kinetics was
observed under the conditions used here when DNAJB6 was
added during the first 30min of the lag-phase; but after 45min,
when the ThT signal starts to increase above the background
noise level (when just over 5% of the A42monomers had con-
FIGURE 4. Prevention of nucleation pathways by the chaperone DNAJB6. Schematic diagram showing (A) the molecular pathways involved in A42
aggregation and (B) the proposedmechanism bywhich DNAJB6 inhibits the aggregation reaction. As indicated in faded colors in B, the interactions between
the chaperone and the A42 growing aggregates inhibit both primary (as seen in Fig. 3A) and secondary (as seen in Fig. 3F) nucleation pathways.
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verted to fibrils), addition of DNAJB6 showed no inhibition of
fibril formation.
DNAJB6 is therefore not able to suppress the aggregation
reaction after a critical concentration of aggregates, sufficient
to deplete the chaperone from solution, has been formed.These
results confirm the existence of a strong interaction between
DNAB6 and A42 aggregates and corroborate the conclusion
that the microscopic mechanism of inhibition of A42 aggre-
gation under these conditions is due to sequestration by the
chaperone of the growing aggregate species. We explicitly ver-
ified the capability of DNAJB6 to bind to A42 aggregates dur-
ing the course of the aggregation reaction through immuno-
chemical analysis of the SDS-insoluble species obtained at the
end of the reactions where DNAJB6 was added after 45, 60, 75,
and 90 min (Fig. 6B). The results show that the maximum
amount of DNAJB6 trapped in the fibrils was observed when
the DNAJB6 was added after 45 min. When the DNAJB6 was
added at later time points, corresponding to
15, 30, and 50%,
respectively, of monomer conversion into fibrils, a progressive
decline in the boundDNAJB6was detectedwith the SDS-insol-
uble species. In addition, in the absence of fibrils no DNAJB6
was trapped on the filtration membrane, whereas pre-formed
A42 fibrils were found to bind DNAJB6 only to a small extent
(Fig. 6C). The latter result indicates that the incorporation of
the chaperone occurs during fibril growth.
The depletion of soluble DNAJB6, due to the high affinity
and the low dissociation rate of the binding to the accumulating
oligomers and fibrils, thus explains the observed loss of the
inhibitory effect at the end stages of the aggregation reaction.
Moreover, this model predicts that a continuous introduction
of small amounts of chaperone during the aggregation reaction
should prolong the inhibitory effect. This hypothesis was con-
firmed by performing aggregation experiments where low con-
centrations of the chaperone were repetitively added at differ-
ent time-points during the aggregation reaction (Fig. 7). The
results show that the addition of DNAJB6 during the aggrega-
tion process prolongs the inhibitory effect both in unseeded
(Fig. 7A) and in seeded reactions (Fig. 7B). For seeded reactions,
however, the inhibitory effect is substantially larger if DNAJB6
FIGURE 5. Incorporation of DNAJB6 into fibrils. Fibril formation by 3M A42 solutions in the absence (A) and presence of 0.04M (B), 0.06M (C), and 0.07
M (D) DNAJB6 were incubated at 37 °C and monitored by ThT fluorescence. Six samples (marked with asterisks) taken at six time points during the fibril
formation process, and one sample withdrawn at the end of the experiments after 24 h, were examined. SDS-insoluble species were trapped on a cellulose
acetate membrane, incubated with antibodies against A42 and DNAJB6, and detected simultaneously with secondary antibodies labeled with different
chromophores.
FIGURE 6. Arrest of ongoing reactions by binding of DNAJB6 to A42
aggregates. A, 0.3MDNAJB6was added to 3MA42 solutions at 0, 15, 30,
45, 60, 75, or 90 min after the initialization of fibril formation at 37 °C. B, SDS-
insoluble fibrils from the reactions in A corresponding to incubation times of
45, 60, 75, and 90 min were withdrawn after 35 h in the platereader and
trapped on a cellulose acetatemembrane, incubatedwith antibodies against
A42 and DNAJB6, and detected simultaneously with secondary antibodies
labeled with different chromophores. C, control experiments for the dual
immunodetection: 1: 3 M A42 fibrils alone, 2: 3 M A42 fibrils mixed with
0.3 M DNAJB6 just prior to trapping, and 3: 0.3 M DNAJB6 alone.
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is added as a single aliquot at the beginning of the reaction (Fig.
7D) relative to the addition of fractions of the same amount at
different time-points (Fig. 7B). This behavior can be rational-
ized by noting that a larger amount of molecular chaperone is
likely to be required at the beginning of the reaction to seques-
ter and deactivate the quantity of seed fibrils introduced into
the reaction mixture. By contrast, for unseeded reactions, the
inhibitory effect was found to be closely similar when the same
total amount of DNAJB6 was added as a single aliquot at the
beginning of the reaction (Fig. 7C) or added at different time
points during the reaction (Fig. 7A). Also, the fact that a specific
amount of DNAJB6 is required for sequestration of a specific
quantity of aggregated A42 rather than a specific threshold
concentration of DNAJB6, indicates that the concentration
of the chaperone, despite being very low relative to that of
the client peptide, is larger than the equilibrium dissociation
constant of binding between the chaperone and the A42
species. As a consequence, DNAJB6 is able to sequester an
amount of oligomers that is proportional to the amount of
DNAJB6. This observation explains the finding that there is
a point in time (between 30 and 45 min in Fig. 6A) where
addition of DNAJB6 no longer inhibits the fibril formation:
the quantity of aggregated and growing A42 species
exceeds that of the chaperone.
To generate a concentration, P, of aggregates sufficient to
replace those sequestered by the chaperone, an additional time
t  P/r0 is required, where r0 is the nucleation rate at the
early stage, which is to a good approximation a constant since
the monomer depletion at this time point is negligible (44).
Such a mechanism should therefore result in an increase in
both the lag-time and the half-time of fibril formation, which is
linearly proportional to the concentration of the chaperone.
This behavior is observed for all the sets of data of both the
unseeded and seeded reactions (Fig. 8).
Taken together, all the data indicate clearly that the molecular
chaperone achieves its remarkably effective and sub-stoichiomet-
ric inhibition by sequestering the A42 oligomeric species (Fig. 4)
generated through both primary and secondary nucleation.
DISCUSSION
DNAJB6 is amember of theHsp40 family ofmolecular chap-
erones involved in a wide range of cellular events. DNAJB6 has
FIGURE 7. Extension of the inhibitory effect for longer times bymultiple additions of DNAJB6. Aliquots of DNAJB6, each giving a concentration of 0.015
M, were added repeatedly into the (A) unseeded and (B) seeded aggregation reactions, from one to seven times at the time points 0, 0.5, 1, 2, 4, 8, and 20 h.
For comparison, the same total amount of DNAJB6 was added at the beginning of the experiment in the (C) unseeded and (D) seeded aggregation reactions.
FIGURE 8. Extension of lag-phase by sequestering of growing A42
aggregates by DNAJB6. The increase in the half-times of the reaction pro-
files shown in Fig. 7 as a function of DNAJB6 concentration. The symbol t0.5*
represents the half-time of the aggregation reaction in the absence of chap-
erone. The linear increase observed for both unseeded and seeded reactions
suggests that DNAJB6 binds to the growing aggregates with high affinity as
described in the main text.
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been identified as a particularly powerful suppressor of polyglu-
tamine aggregation and of its associated toxicity in a screen that
compared different types of chaperones, namely HSPA
(Hsp70), HSPH (Hsp110), and DNAJ (Hsp40) (48). DNAJB6 is
effective at sub-stoichiometric levels both in vitro and in human
cell lines, suggesting that DNAJB6 is a peptide chaperone that
interacts with polyglutamine peptides released from the pro-
teasome (34, 49).
In the present work, we have demonstrated that DNAJB6
inhibits the aggregation of another and even more aggrega-
tion-prone peptide, A42, at remarkably low sub-stoichio-
metric molar ratios of chaperone to peptide and identified
the molecular inhibition mechanism underlying this potent
activity, which is notably significantly larger than the inhib-
itory activity of human B-crystallin and HSA at corre-
sponding molar ratios (Fig. 1). Analysis of the aggregation
kinetics shows that DNAJB6 can impede the growth and the
autocatalytic self-multiplication of A42 fibrils in both
unseeded and seeded reactions, thereby showing that inhi-
bition of the reaction must involve suppressing both the
nucleation and the growth processes involved with A42
aggregation reaction (Fig. 4). Stoichiometric considerations
suggest that the chaperone interacts with aggregated forms
of the peptide rather than with monomers, a mechanism
confirmed by immunoblot analysis, which indicates that
DNAJB6 is incorporated into the growing fibrils (Figs. 5 and
6). As a consequence, at low sub-stoichiometric values the
chaperone is depleted from the solution, leading to the dis-
appearance of its inhibitory effect over time. This conclusion
was confirmed by kinetic experiments in which the intro-
duction of DNAJB6 into the system at regular time intervals
prolongs the inhibitory effect (Fig. 7). In particular, an equiv-
alent inhibitory effect was observed when the same total
amount of DNAJB6 was added as a single aliquot at the
beginning of the reaction (Fig. 7C) as when it was added in a
progressive manner at different time points (Fig. 7A) over
the course of the reaction. This observation indicates further
that DNAJB6 binds with high affinity to the growing aggre-
gates, a finding supported by the linear increase in the dura-
tion of the lag-phase as a function of chaperone concentra-
tion in reaction profiles at both unseeded and seeded
conditions (Fig. 8).
The specific nature of the interactions between the chap-
erone and specific types of protein aggregates at the molec-
ular level, as well as the correlation with the chaperone struc-
ture, remain to be elucidated. DNAJB6 has a conserved
N-terminal HSPA-interacting J-domain, characteristic of all
DNAJ protein family members, a G/F-rich central domain
and a C-terminal segment which is inferred to be a peptide-
binding domain. An S/T-rich region in the beginning of the
C-terminal domain, conserved only among DNAJB6 and
DNAJB8 proteins, was observed to be important for the sup-
pression of the aggregation of Huntingtin exon-1 and for the
formation of oligomers (48). In contrast with DNAJB6, the
canonical Hsp40 chaperone DNAJB1 has by itself an insig-
nificant effect on the aggregation kinetics of A42, although
it acts to enhance the aggregation inhibition effect of an
Hsp70 homolog (50). DNAJB1 also has only a very minor
effect on the aggregation of polyglutamine peptides (34, 48),
emphasizing the large difference in specificity and function-
ality among the various members of the large and highly
diverse DNAJ-protein family (51). Since the largest differ-
ence in sequence between DNAJB1 and DNAJB6 is in the
C-terminal domain, this observation supports a possible
dominant role of this domain in the interactions with mis-
folded species, which are likely to be mediated by hydropho-
bic forces. Indeed, charged hydrophilic proteins with both
negative and positive net charges, including proteins with a
similar net charge to that of DNAJB6, are much less potent
inhibitors of amyloid formation than DNAJB6 (52). This
implies that long-range electrostatic effects play only a
minor role in the specific interactions with initially formed
aggregates. Interactions with solvent exposed hydrophobic
residues in the aggregated A42 species (53, 54), are there-
fore likely to underlie the sequestration of the initial prod-
ucts of the primary and secondary nucleation reactions of
A42 by DNAJB6, a process which may involve regions of
DNAJB6 that can be buried in oligomeric states of DNAJB6
itself. The prevalence of hydroxyl groups in the conserved
S/T region is another intriguing feature that may provide
high capacity hydrogen bonding to edge strands of growing
aggregates.
We conclude that DNAJB6 inhibits A42 fibril formation at
low sub-stoichiometric ratios by interacting selectively with the
most reactive species present in the system, in particular by
sequestering the aggregated species generated by primary or
secondary nucleation. This result highlights an intriguing fea-
ture of the activity of a natural molecular chaperone against
misfolding events and associated reactions, suggesting that the
roles of chaperones are not limited to the sequestration of single
monomeric unfolded conformations, but can involve multiple
interactions with aggregated species.
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